In as many months, the MHRA has approved two oral GLP-1 tablets for weight management. The first, a semaglutide (known commercially as the Wegovy pill), and more recently orforglipron (sold under the name Foundayo), making the UK the first country in Europe to approve this latest oral GLP-1 medication. I spent years at Novo Nordisk watching GLP-1s move from specialist clinics into mainstream medicine. Back then, it felt fast paced, but it doesn’t compare to the speed the market is travelling at today.

This latest oral GLP-1 approval follows the approval of a higher dose of Wegovy, 7.2mg, the highest yet cleared for use in the UK, and sits ahead of a pipeline that includes triple agonists and additional once-daily tablets from other manufacturers, all expected within the next eighteen months.

The coverage of each approval individually is straightforward. A higher dose of Wegovy means more options for patients who plateau on existing doses. Oral GLP-1s provide an alternative for people who have avoided treatment by injection, with orforglipron, a once-daily tablet with no food or water restrictions adding another formulation to a growing list. All are genuine clinical advances and worth welcoming. 

However, it is also clear that patients and clinicians increasingly choosing between all of these at once, creating complexity and the question, “what is the right pathway?”.

A patient beginning care today may be choosing between treatments, doses and delivery methods all at once, often before their care team has real world data on how those options perform against each other in anything but a trial population. That is not a criticism of the drugs, but a reflection of how fast this market is moving relative to the infrastructure meant to guide people through it.

The clinical reality hasn’t changed. Dose escalation still needs supervision, and side effects still need to be managed as they emerge, before a patient decides to stop taking their medication. Switching between formulations is also a decision that requires clinical judgement.

More choice raises the bar for what good clinical support has to do, because there are now more points in a patient’s journey where the wrong decision, or no decision at all, can undo the benefit of the medicine itself.

Every new approval is reported as a step forward for patients, and it is. But a drug only delivers the outcome it is capable of if the person taking it is properly supported through dose changes, side effects and the inevitable plateaus. The more options there are, the more that support has to become personalised around individual patients rather than assume one pathway fits everyone.

In practice, that means clinicians who can talk a patient through why one dose or formulation suits them over another, and teams who stay in contact long enough to catch a plateau or side effect before it becomes a reason to stop treatment.

The next phase of this market will be decided by clinicians who can guide patients through the choices in front of them and support them through their personalised journey and keep patients in treatment long enough for any of these treatments to deliver the outcomes they are capable of.